Castle biosciences presents new data at asds from prospective, multicenter connection study supporting use of decisiondx®-melanoma to guide slnb decisions in t1a tumors with high-risk features and t1b tumors

Friendswood, texas--(business wire)---- $cstl #asds--castle will share new data at asds supporting the clinical utility of its decisiondx-melanoma and decisiondx-scc tests.

CSTL Ratings Summary

CSTL Quant Ranking